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SPIRONOLACTONE AND CANRENOATE: 
DIFFERENT ANTIALDOSTERONIC 
DIURETIC AGENTS 
Andriulli A, Arrigoni A, Gindro T, Karbowiak I ,  
Buzzetti G, Armanini D.  Canrenone and androgen 
receptor-active materials in plasma of cirrhotic patients 
during long-term K-canrenoate or spironolactone ther- 
apy. Digestion 1989;44:155-162. 
ABSTRACT 
Plasma levels of canrenone and androgen receptor- 
active materials (ARM) were determined during 
long-term oral K-canrenoate or spironolactone ther- 
apy in cirrhotics with chronic recurrent ascites. Mean 
plasma canrenone level was approximately 3 times 
higher under K-canrenoate than under spironolac- 
tone treatment; moreover, the levels were not dose 
related. Either type of treatment did not affect plasma 
aldosterone and testosterone concentrations. Plasma 
ARM during K-canrenoate treatment did not change, 
whereas in the spironolactone group a 3-fold increase 
of ARM occurred (p < 0.05). No dose-related effect was 
evident with the latter treatment. The lower incidence 
of gynecomastia in the K-canrenoate group was not 
correlated with values of plasma canrenone or ARM 
(p > 0.05). 
Our study questions the traditional view that the 
mode of action of spironolactone is via its metabolite 
canrenone. The two antialdosterone drugs, although 
equally effective in clearing ascites from cirrhotics, 
appear to act through partially different metabolites. 
The lower incidence of antiandrogenic or estrogen-like 
side effects during K-canrenoate seems to be related to 
metabolites other than canrenone itself. 
COMMENTS 
The concept of “sequential therapy” for the treatment 
of sodium and water retention in cirrhotic patients with 
ascites is widely accepted (1). Although loop diuretics are 
in general quantitatively more potent than antialdos- 
teronic agents, the latter are much more effective in 
inducing natriuresis in cirrhotic patients with ascites 
and are, therefore, considered to be the treatment of 
choice (2). Moreover, their potassium-sparing effect is 
particularly useful in this clinical setting, which is 
characterized by potassium depletion. Antialdosteronic 
agents directly and specifically counteract the distal 
tubular effects of secondary hyperaldosteronism. 
However, they are also effective in cirrhotic patients 
with normal renin and aldosterone levels (31, as shown 
in the paper by Andriulli et al. In such patients, an 
increased sensitivity to aldosterone in the distal and 
collecting tubules has been hypothesized. It is pos- 
999 
1000 HEPATOLOGY Elsewhere HEPATOLOGY 
sible, however, that antialdosteronic substances act 
by different mechanisms. It has been shown that 
K-canrenoate can stimulate renal prostaglandin and 
kinin synthesis in hypertensive patients (4). It is 
therefore also conceivable that in cirrhotic patients the 
natriuretic action of this drug is associated with in- 
creased intrarenal production of vasodilating autacoids 
that play a “protective” role against activated vasocon- 
strictive and sodium-retaining factors such as catechol- 
amines, angiotensin I1 and thromboxane A, (5). 
The paper by Andriulli et al. deals with another effect 
of antialdosteronic agents, their antiandrogenic activity. 
This action is responsible for most of the common side 
effects that occur after prolonged administration, par- 
ticularly the development of gynecomastia. In this 
study, the antiandrogenic effect of spironolactone and 
K-canrenoate was documented by the demonstration of 
gynecomastia and the determination of circulating 
androgen receptor-active material (ARM) using a pre- 
viously described radioreceptor assay (6). In addition, 
plasma levels of canrenone, testosterone and aldo- 
sterone were determined every 3 mo during prolonged 
administration of minimal doses of spironolactone or 
K-canrenoate (100 mg daily or on alternate days for 
1 yr) in cirrhotic patients with ascites. Cirrhotic 
patients treated with K-canrenoate showed significantly 
higher levels of plasma canrenone, confirming that 
this compound is not likely to be the main metab- 
olite of spironolactone (7). Indeed, metabolism of 
spironolactone leads to  the formation of several 
sulfur-containing moieties, especially 7-a-thiomethyl- 
spironolactone. All these metabolites have antimineral- 
corticoid and antiandrogenic activity. On the other 
hand, canrenone and canrenoic acid, which are the main 
metabolic products of K-canrenoate metabolism, are not 
sulfur-containing metabolites, a feature that could 
explain the low antiandrogenic activity of K-canrenoate. 
In addition, circulating levels of ARM increase in 
patients treated for 3 mo with spironolactone, whereas 
they remain unchanged after K-canrenoate. This latter 
therapy is characterized by a lower incidence of gyneco- 
mastia, although a clear correlation with plasma can- 
renone and ARM levels was not seen. Furthermore, in 
contrast to other reports (8), antialdosteronic therapy, 
probably because of the low doses used, does not affect 
plasma testosterone levels. Studies of animals (9) and of 
hypertensive patients (8) have suggested that the anti- 
androgenic activity of spironolactone may be caused by 
a decreased testosterone biosynthesis. The authors do 
not provide information about the degree of hepatic and 
renal function impairment. Also, it would have been 
desirable to have evaluated the effects of higher doses of 
spironolactone and K-canrenoate used in clinical 
practice. 
In conclusion, the paper by Andriulli et al. provides 
some pharmacological evidence for the preferential use 
of K-canrenoate in the management of avid sodium and 
water retention in cirrhotic patients with ascites. In 
addition, the results of this study are in agreement with 
a previous report by Francavilla et al. (10) that showed 
a drastic reduction of liver androgen-receptor activity in 
rats treated for a prolonged period with spironolactone 
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ABSTRACT 
In a prospective study of the natural history of 
congestive gastropathy, 212 consecutive cirrhotic pa- 
tients (75 treated with sclerotherapy) were included. 
Mean follow-up was 46 months. Mild gastropathy (mo- 
saiclike pattern) was found in 110 patients and severe 
gastropathy (granular mucosa with cherry spots) was 
found in 20. Prevalence of Helicobacterpylori, formerly 
Campylobacter pylori, was 50% in patients without, 
43% in those with mild, and 28% in those with severe 
gastropathy. Congestive gastropathy was significantly 
more frequent in patients treated with sclerotherapy 
(83% vs. 50%, P < Sixty-month actuarial propor- 
